HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Germany’s OTC Market In 2023: Cough, Cold & Flu and Probiotics Drove Steady Growth

Executive Summary

German consumers are “generally willing to accept price increases from OTC manufacturers” when it comes to core categories like cough, cold & flu, finds Sempora, and are increasingly willing to shell out for trending gut health products like probiotics.

You may also be interested in...



ENVI: Prescription Requirement Only With Evidence Of Antimicrobial Resistance

The EU Parliament's Environment, Public Health and Food Safety committee proposes a “compromise amendment” to the new pharmaceutical directive that would include only antimicrobials for which there is an “identified risk of antimicrobial resistance” to the prescription requirement. 

Why Did Germany’s Switch Committee Reject Perrigo’s OTC Daily Contraceptive Proposal?

Skepticism about the need for widening access to the progestogen-only contraceptive pill, fears of associated thrombosis risk with use and the potential cost barriers were among the many reasons for the unanimous rejection of Perrigo's Rx-to-OTC switch application for desogestrel (75μg) for oral use.

Over The Counter 2 Apr 2024: Analyzing The Spin-Out Trend In Consumer Health, With HBW’s Malcolm Spicer And Tom Gallen

In this episode, HBW Insight’s Europe and US editors bring their expertise to bear on the current the trend towards standalone OTC companies in global consumer health. We look at four major players: Haleon, which separated from GSK almost two years ago; Kenvue, soon to celebrate its first anniversary as a new company; Sanofi Consumer Healthcare, which is poised to split from its pharma parent; and Bayer, which has decided to buck the trend, holding on to its consumer health division. We discuss some of the advantages of becoming a standalone company, for example in leaning into a wider concept of self-care.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS154450

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel